Carbamazepine (All indications)

Neural Tube Defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9653
R34358		 Bànhidy (Carbamazepine), 2011 Neural tube defects throughout pregnancy case control unexposed, sick Adjustment: No Matched 2.00 [0.16;25.76] C 2/12   1/11 3 12
ref
Total 1 studies 2.00 [0.16;25.76] 3 12
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bànhidy (Carbamazepine), 2011Bànhidy, 2011 1 2.00[0.16; 25.76]3120%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 2.00[0.16; 25.76]312 -NABànhidy (Carbamazepine), 2011 1 Type of controls unexposed, sickunexposed, sick 2.00[0.16; 25.76]312 -NABànhidy (Carbamazepine), 2011 1 Tags Adjustment   - No  - No 2.00[0.16; 25.76]312 -NABànhidy (Carbamazepine), 2011 1 MatchedMatched 2.00[0.16; 25.76]312 -NABànhidy (Carbamazepine), 2011 1 All studiesAll studies 2.00[0.16; 25.76]312 -NABànhidy (Carbamazepine), 2011 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.44[0.06; 35.82]166 -NAMawer (Carbamazepine) (Controls unexposed, disease free), 2010 1 unexposed, sick controlsunexposed, sick controls 1.14[0.24; 5.44]55520%NAVajda (Carbamazepine) (Controls unexposed, sick), 2013 Bànhidy (Carbamazepine), 2011 Mawer (Carbamazepine) (Controls unexposed, sick), 2010 Canger (Carbamazepine), 1999 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.96[1.11; 7.85]205,0740%NATomson (Carbamazepine), 2018 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Vajda (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 Mawer (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 50.510.01.0